Biotech Values

[DewDiligence]

PFE reports phase-2b data_for_lead Metsera drug, a long-acting GLP-1 agonist:

https://www.businesswire.com/news/home/20260202566685/en/Pfizers-Ultra-Long-Acting-Injectable-GLP-1-RA-Shows-Robust-and-Continued-Weight-Loss-with-Monthly-Dosing-in-Phase-2b-Trial

• VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher dosing regimens in Phase 3.

• Study met primary endpoint of statistically significant weight reduction at 28 weeks with a competitive tolerability profile [but see details below—Dew].

• Weight loss continued after pre-planned switch from weekly to monthly dosing, with no plateau observed at 28 weeks.

• 10 Phase 3 trials with PF’3944 expected to advance in 2026; expansive clinical development program underway with 20+ planned and ongoing studies across diverse obesity pipeline.

At week 28, 10% and 12.3% placebo-adjusted weight loss was achieved in Arms 1 and 3 respectively, which are the low and medium monthly maintenance dosing regimens planned for inclusion in Phase 3. These data show robust and continuous weight loss after switching to monthly dosing, with no plateau observed at week 28, suggesting continued weight loss is expected as the study continues through week 64.

… Across Arms 1 and 3, five total participants discontinued from treatment due to adverse events in the weekly phase and five total participants discontinued from treatment due to AEs in the monthly phase [i.e. 10 discontinuations all told from these trial arms]. There were zero discontinuations from treatment due to AEs in the placebo group.

The full dataset will be presented at the ADA conference on 6/6/26.